Back
TScan Therapeutics 10K Form
Sell
43
TCRX
TScan Therapeutics
Last Price:
$1.81
Seasonality Move:
-22.79%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive TCRX News And Ratings
See the #1 stock for the next 7 days that we like better than TCRX
TCRX Financial Statistics
Sales & Book Value
Annual Sales: | $2.8M |
---|---|
Cash Flow: | $-39.1M |
Price / Cash Flow: | 0 |
Annual Sales: | $3.71 |
Price / Book: | 0.45 |
Profitability
EPS (TTM): | -1.09000 |
---|---|
Net Income (TTM): | $-131.5M |
Gross Margin: | -- |
Return on Equity: | -62.11% |
Return on Assets: | -39.42% |
TScan Therapeutics Earnings Forecast
Key TScan Therapeutics Financial Ratios
-
The Research & Development expenses have been 3,812.14% of Revenue.
-
The Net Earning history of TCRX is -4,527.66% of Total Revenues.
-
Per Share Earnings over the last 6 years have been positive in 3 years.
TScan Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | TCRX |
Website: | tscan.com |
Debt
Debt-to-Equity Ratio: | 0.15 |
---|---|
Current Ratio: | 8.55 |
Quick Ratio: | 8.44 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
TCRX Technical Analysis vs Fundamental Analysis
Sell
43
TScan Therapeutics (TCRX)
is a Sell
Is TScan Therapeutics a Buy or a Sell?
-
TScan Therapeutics stock is rated a SellThe current TScan Therapeutics [TCRX] share price is $1.80. The Score for TCRX is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.